Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2024-Results/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2024-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-Jefferies-Global-Healthcare-Conference/default.aspx
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Late-Breaker-Oral-Presentation-at-Digestive-Disease-Week-Reinforces-Potential-of-Once-Weekly-Apraglutide-for-Adults-with-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF/default.aspx
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-First-Quarter-2024-Results/default.aspx
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-JMP-Life-Sciences-Conference/default.aspx
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Present-New-Data-on-Once-Weekly-Apraglutide-in-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF-at-Digestive-Disease-Week-2024/default.aspx
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2024-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Results-from-its-Phase-II-Exploratory-STARGAZE-Trial-of-Apraglutide-in-Patients-with-Steroid-Refractory-Gastrointestinal-Acute-Graft-versus-Host-Disease-SR-GI-aGVHD/default.aspx
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Topline-Results-from-Global-Phase-III-Trial-of-Once-Weekly-Apraglutide-in-Adults-with-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF/default.aspx